Skip to content

Explore the latest news and publications from Latigo Biotherapeutics

Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors

Former William Blair partner and group head, Lugo has facilitated raising more than $6 billion…

Read more

Latigo Biotherapeutics Announces Positive Phase 1 Data for 
Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Singla, M.D., Chief Medical Officer

Positive Phase 1 results for LTG-001, Latigo’s potential best-in-class non-opioid Nav1.8 inhibitor, demonstrated it to…

Read more

Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth

Farzan brings more than two decades’ leadership experience with a strong track record in fundraising…

Read more

Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action

Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders.
Read more

Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines

Potential best-in-class lead program targets Nav1.8, a validated human target for pain.
Read more
Back To Top